DLH Holdings Corp. (DLHC) Stock Analysis and Metrics

DLH Holdings

NASDAQ: DLHC

$5.11 ▲ +0.04 (+0.79%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap73.91 Mn

P/E-16.46

P/S0.25

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)129.96 Mn

Revenue Growth (1y) (Qtr)-33.57

Add ratio to table…

About

DLH Holdings Corp. delivers improved health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. The company leverages cyber technology, artificial intelligence, advanced analytics, cloud based applications, and telehealth systems to support civilian and military agencies. Its core activities include modernizing IT infrastructure, protecting sensitive data, conducting scientific research, and engineering complex systems for the Department of Health and Human Services, the Department of Veterans Affairs, and the Department of Defense.

DLH Holdings Corp. generates revenue primarily by providing services under prime contracts awarded by the U. S. federal government through competitive bidding. The company offers three main service lines: Digital Transformation and Cyber Security, Science Research and Development, and Systems Engineering and Integration. Revenue is derived from time and materials contracts (51.4%), firm fixed price contracts (27.2%), and cost reimbursable contracts (21.4%). The customer base consists of federal agencies that require technology modernization, scientific research, and engineering support.

The company operates through the following segments:

• Digital Transformation and Cyber Security: Provide critical digital transformation and cyber security solutions across federal civilian and cyber defense communities, leveraging artificial intelligence, machine learning, cloud enablement, cybersecurity ecosystem, big data analytics, and modeling and simulation to modernize obsolete systems, protect sensitive information, manage large datasets, and enhance operational efficiency.

• Science Research and Development: Advance scientific knowledge through large scale data analytics, testing and evaluation, clinical trials research services, and epidemiology studies for HHS components including NIH and CDC, as well as the Military Health System, using evidence based methods and web technology to support health equity and public engagement.

• Systems Engineering and Integration: Deliver engineering solutions encompassing C5ISR, modeling simulation and training, performance based logistics, system modernization, technology powered health solutions and software engineering for customers such as the US Navy, HHS, VA, and other federal agencies, using automation to accelerate infrastructure innovation and establish lifecycle standards for version control, testing, and release processes.

DLH Holdings Corp. holds a competitive position in the federal government contracting sector by leveraging a highly credentialed workforce, predominantly acting as prime contractor, and maintaining a strong past performance record across its contracts. The company benefits from bipartisan support for key contracts and from proprietary assets such as the Infinibyte cloud based system and CMMI level 3 certification. Its competitors include large firms such as Accenture Federal Services LLC, BAE Systems plc, Booz Allen Hamilton Holding Corp., CACI International Inc., Deloitte, ECS Federal LLC, General Dynamics Information Technology Inc., Guidehouse, IBM Federal, Leidos Holdings Inc., ManTech International Corp., Peraton Inc., SAIC Inc., and Westat Inc., as well as numerous smaller specialized providers. DLH differentiates itself through its integrated people, processes, and technology approach and its track record of delivering best value solutions on a best value basis.

DLH Holdings Corp. serves the U. S. federal government as its primary customer base, with revenue concentrated in three major agencies. The Department of Health and Human Services accounted for 49.8% of total revenue, the Department of Veterans Affairs for 33.8%, and the Department of Defense for 15.5% in the fiscal year ended September 30, 2025. Additional revenue came from smaller federal entities each contributing less than 10% of total sales.

Investment Thesis

▲ Bull case

DLHC is positioned to capture significant upside from the delayed federal procurement cycle that is now materializing after years of disruption, with the company's recent success in securing a two-year sole-source NIH extension demonstrating its enduring value in critical public health missions and providing near-term revenue visibility that the market is overlooking. Despite revenue contraction in Q2 FY26 due to small business set-aside transitions, the company maintained a resilient 9% adjusted EBITDA margin through disciplined cost management, and its debt reduction progress—lowering total debt to $132.7 million from $136.6 million quarter-over-quarter—reflects operational discipline that will amplify free cash flow as delayed contract awards begin to convert to revenue in the back half of FY26 and into FY27, creating a leveraged earnings recovery that investors have not yet priced in given the current focus on year-over-year revenue declines. The administration's FY27 budget request for historic defense and intelligence spending increases, coupled with executive actions to streamline contracting and shift toward fixed-price performance-based contracts, directly aligns with DLHC's core strengths in C4ISR systems, digital modernization, AI/ML, and cybersecurity, positioning the company to win a disproportionate share of new opportunities as pent-up demand from stalled 2024–2025 procurements finally reaches decision points, a catalyst that remains underappreciated by the market still fixated on legacy contract losses. The company's strategic investments in Cyclone and Nexus Labs—cloud-secure digital sandboxes for rapid prototyping and AI integration—are uniquely suited to meet evolving federal priorities in interoperability, zero trust architectures, and mission command systems, giving DLHC a differentiated edge in competitive bids that traditional contractors lack, and this technological moat is not reflected in current valuation multiples which continue to treat the company as a commoditized government services provider rather than an innovation-driven growth play. Finally, DLHC's workforce and project management excellence, repeatedly acknowledged by customer and industry awards for automation, AI, and data science initiatives, represent an intangible asset that enables higher win rates and margin expansion on new work, yet the market continues to discount the company based solely on top-line pressure from transitional headwinds, failing to recognize that the underlying engine of innovation and execution is stronger than ever and poised to accelerate as the federal procurement environment normalizes.

DLHC is positioned to capture significant upside from the delayed federal procurement cycle that is now materializing after years of disruption, with the company's recent success in securing a two-year sole-source NIH extension demonstrating its enduring value in critical public health missions and providing near-term revenue visibility that the market is overlooking. Despite revenue contraction in Q2 FY26 due to small business set-aside transitions, the company maintained a resilient 9% adjusted EBITDA margin through disciplined cost management, and its debt reduction progress—lowering total debt to $132.7 million from $136.6 million quarter-over-quarter—reflects operational discipline that will amplify free cash flow as delayed contract awards begin to convert to revenue in the back half of FY26 and into FY27, creating a leveraged earnings recovery that investors have not yet priced in given the current focus on year-over-year revenue declines. The administration's FY27 budget request for historic defense and intelligence spending increases, coupled with executive actions to streamline contracting and shift toward fixed-price performance-based contracts, directly aligns with DLHC's core strengths in C4ISR systems, digital modernization, AI/ML, and cybersecurity, positioning the company to win a disproportionate share of new opportunities as pent-up demand from stalled 2024–2025 procurements finally reaches decision points, a catalyst that remains underappreciated by the market still fixated on legacy contract losses. The company's strategic investments in Cyclone and Nexus Labs—cloud-secure digital sandboxes for rapid prototyping and AI integration—are uniquely suited to meet evolving federal priorities in interoperability, zero trust architectures, and mission command systems, giving DLHC a differentiated edge in competitive bids that traditional contractors lack, and this technological moat is not reflected in current valuation multiples which continue to treat the company as a commoditized government services provider rather than an innovation-driven growth play. Finally, DLHC's workforce and project management excellence, repeatedly acknowledged by customer and industry awards for automation, AI, and data science initiatives, represent an intangible asset that enables higher win rates and margin expansion on new work, yet the market continues to discount the company based solely on top-line pressure from transitional headwinds, failing to recognize that the underlying engine of innovation and execution is stronger than ever and poised to accelerate as the federal procurement environment normalizes.

▼ Bear case

DLHC faces persistent and underappreciated risks from the structural shift in federal procurement toward small business set-asides, which has permanently eroded its access to large, high-margin contracts like VA CMOP and Head Start, and despite management's optimism about delayed 2024–2025 procurements returning, there is no evidence that these opportunities will materialize at scale or with favorable terms, especially given the administration's stated intent to offset defense spending increases with unspecified reductions in federal health spending—a direct threat to DLHC's public health pillar where the NIH sole-source extension is merely a temporary bridge, not a long-term solution, leaving the company vulnerable to future recompete losses in its most stable revenue stream. The company's reliance on cost-scaling initiatives to maintain margins is a red flag, as repeated rounds of right-sizing suggest an inability to grow organically without cutting expenses, and while CFO Kathryn Johnbull claimed material reductions are complete, the lack of specificity around ongoing real estate and lease evaluations implies further downward pressure on SG&A is likely, which could undermine morale and innovation capacity just as the company needs to invest in emerging technologies like AI and zero trust to remain competitive in evolving federal priorities. Furthermore, DLHC's highlighted strengths in C4ISR, digital transformation, and cybersecurity are increasingly commoditized as the defense and intelligence sector floods with new entrants and legacy contractors accelerating their own digital modernization efforts, meaning the company's once-differentiated capabilities in data science and AI/ML may no longer command premium pricing or win rates, especially as procurement shifts toward fixed-price contracts that transfer performance risk to the vendor—a shift that benefits larger, more scale-advantaged players with deeper pockets to absorb cost overruns. The NIH contract extension, while framed as a positive, is a double-edged sword: it provides short-term relief but signals that the agency avoids full recompete due to perceived risks or lack of competitive alternatives, which could indicate weakening confidence in DLHC's ability to win such work openly, and the two-year term creates a cliff edge where revenue could drop sharply if not renewed, yet management offered no clarity on post-extension plans or pipeline health in public health beyond this bridge arrangement. Finally, the company's debt reduction progress, while superficially positive, is being driven by austerity rather than growth, with free cash flow generation dependent on squeezing working capital and delaying investments, and the expectation to convert 50–55% of EBITDA to debt repayment leaves minimal fuel for reinvestment in R&D, acquisitions, or talent retention—critical needs in a sector where technological obsolescence occurs rapidly—meaning DLHC is trading long-term competitiveness for short-term balance sheet optics, a strategy that may sustain appearances but ultimately undermines its ability to compete for the high-value, complex work it claims to target.

DLHC faces persistent and underappreciated risks from the structural shift in federal procurement toward small business set-asides, which has permanently eroded its access to large, high-margin contracts like VA CMOP and Head Start, and despite management's optimism about delayed 2024–2025 procurements returning, there is no evidence that these opportunities will materialize at scale or with favorable terms, especially given the administration's stated intent to offset defense spending increases with unspecified reductions in federal health spending—a direct threat to DLHC's public health pillar where the NIH sole-source extension is merely a temporary bridge, not a long-term solution, leaving the company vulnerable to future recompete losses in its most stable revenue stream. The company's reliance on cost-scaling initiatives to maintain margins is a red flag, as repeated rounds of right-sizing suggest an inability to grow organically without cutting expenses, and while CFO Kathryn Johnbull claimed material reductions are complete, the lack of specificity around ongoing real estate and lease evaluations implies further downward pressure on SG&A is likely, which could undermine morale and innovation capacity just as the company needs to invest in emerging technologies like AI and zero trust to remain competitive in evolving federal priorities. Furthermore, DLHC's highlighted strengths in C4ISR, digital transformation, and cybersecurity are increasingly commoditized as the defense and intelligence sector floods with new entrants and legacy contractors accelerating their own digital modernization efforts, meaning the company's once-differentiated capabilities in data science and AI/ML may no longer command premium pricing or win rates, especially as procurement shifts toward fixed-price contracts that transfer performance risk to the vendor—a shift that benefits larger, more scale-advantaged players with deeper pockets to absorb cost overruns. The NIH contract extension, while framed as a positive, is a double-edged sword: it provides short-term relief but signals that the agency avoids full recompete due to perceived risks or lack of competitive alternatives, which could indicate weakening confidence in DLHC's ability to win such work openly, and the two-year term creates a cliff edge where revenue could drop sharply if not renewed, yet management offered no clarity on post-extension plans or pipeline health in public health beyond this bridge arrangement. Finally, the company's debt reduction progress, while superficially positive, is being driven by austerity rather than growth, with free cash flow generation dependent on squeezing working capital and delaying investments, and the expectation to convert 50–55% of EBITDA to debt repayment leaves minimal fuel for reinvestment in R&D, acquisitions, or talent retention—critical needs in a sector where technological obsolescence occurs rapidly—meaning DLHC is trading long-term competitiveness for short-term balance sheet optics, a strategy that may sustain appearances but ultimately undermines its ability to compete for the high-value, complex work it claims to target.

Contract with Customer, Basis of Pricing Breakdown of Revenue (2025)

Peer Comparison

Companies in the Specialty Business Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	CTAS	Cintas Corp	82.43 Bn	0.00 Mn	0.00 Mn	2.66 Bn
2	RTO	Rentokil Initial Plc /Fi	71.81 Bn	0.00 Mn	0.00 Mn	5.57 Bn
3	RELX	Relx Plc	63.28 Bn	11.42 Mn	6.29 Mn	-
4	TRI	Thomson Reuters Corp /Can/	40.35 Bn	0.00 Mn	0.00 Mn	1.56 Bn
5	CPRT	Copart Inc	26.32 Bn	0.00 Mn	0.00 Mn	-
6	GPN	Global Payments Inc	22.09 Bn	0.00 Mn	0.00 Mn	22.57 Bn
7	RBA	Rb Global Inc.	20.79 Bn	0.00 Mn	0.00 Mn	2.32 Bn
8	ULS	UL Solutions Inc.	17.26 Bn	0.00 Mn	0.00 Mn	0.36 Bn

Research Tools

Developers

About

Investment Thesis

Concentration Risk Benchmark Breakdown of Revenue (2025)

Contract with Customer, Basis of Pricing Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Concentration Risk Benchmark Breakdown of Revenue (2025)

Contract with Customer, Basis of Pricing Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password